Cleveland Clinic

Discover the latest advancements in diabetes technology from November 2025, including Omnipod updates and the new Pivot pump.

Explore the latest findings on GLP-1 drugs, including their impact on Alzheimer's and promising results for type 1 diabetes treatment.

This episode covers the upcoming release of Dexcom's G7 15-day patch and major price cuts for semaglutide.

Discover groundbreaking findings from the FINE-ONE trial on finerenone, offering hope for type 1 diabetes patients with CKD.

This episode covers the recent approval of oral semaglutide for T2D and a pre-specified subanalysis of the SELECT trial.

This episode covers the upcoming glucose monitor Biolinq Shine, the Insulin Icodec FDA resubmission, and the end of Eli Lilly's work in T2D.

Celebrate 150 episodes of Diabetes Dialogue as hosts reflect on advancements in diabetes technology and impactful discussions in patient care.

The Q3 recap for endocrinology spotlights major FDA decisions, new guidelines for managing diabetes during pregnancy, and major clinical trial updates.

Catch up on FDA decisions, critical trial results, and expert perspectives on endocrinology.

This episode highlights the recent technological advancements made by Medtronic Diabetes in treating type 1 and 2 diabetes.

This episode highlights the results of the ATTAIN-1 and STEP UP clinical trials, examining the potential of their respective GLP-1 RA subjects.

Explore the latest advancements in diabetes technology, including FDA-approved insulin pumps and innovative CGMs for weight management.

Hosts explore the latest findings on GLP-1 medications, semaglutide and tirzepatide, from ESC Congress 2025.

One year after neffy's approval, 4 clinicians and 1 PharmD examine its continuing impact on the field.

In the final segment of this 5-part HCPLive RX Review, experts discuss real-world barriers to implementing new C3G therapies and lingering unmet needs.

In part 4 of this 5-part HCPLive RX Review, experts discuss how the availability of new therapeutic options are changing the treatment paradigm in C3G.

In part 3 of this 5-part HCPLive RX Review, experts discuss VALIANT data supporting pegcetacoplan’s approval and how they compare to iptacopan.

In part 2 of this 5-part HCPLive RX Review, experts discuss how to utilize the newly FDA-approved therapies for treating C3G and what questions remain.

In part 1 of this 5-part HCPLive RX Review, experts discuss the current therapeutic landscape for C3G following 2 notable FDA approvals.

In this video, the last in a 6-part series, panelists discuss the potential future impact of biologics in the COPD field.

In this video, the fifth in a 6-part series, panelists discuss the factors that influence initiating biologics for COPD.

In this video, the fourth in a 6-part series, panelists discuss how future studies of monoclonal antibodies in COPD could be refined.

In this video, the third in a 6-part series, panelists discuss how learnings from asthma management are informing COPD management.

In this video, the second in a 6-part series, panelists discuss using monoclonal antibodies in early-line COPD treatment.

In this video, the first in a 6-part series, panelists discuss the impact of monoclonal antibodies for COPD management.

In this video, the last in a 4-part series, panelists discuss how ongoing research and efforts could shape the future of ATTR-CM management.

In this video, part 3 of a 4-part series, panelists discuss the impact of recent approvals and pipeline developments on the outlook for ATTR-CM management.

In this video, part 2 of a 4-part series, panelists discuss on recent advancements in imaging and biomarker-based diagnostics for ATTR-CM

In this video, part 1 of a 4-part series, panelists discuss recent advancements in ATTR-CM management.

In this video, part 5 of a 5-part series, panelists discuss emerging innovations in food allergy and anaphylaxis research poised to reshape clinical practice.